MedTrace Logo

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

NCT00224133 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 661

Last updated 2010-04-27

Study results available
· View outcomes & findings →

Summary

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

Silodosin

8 mg daily

Sponsors & Collaborators

  • Watson Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Lawrence Hill, Pharm D, RPh · Watson Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00224133 on ClinicalTrials.gov